DDInter1665 DDInter856
Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease.
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated heparin is more specific than LMWH for thrombin. Furthermore, the effects of UH can typically be reversed by using protamine sulfate.
Sibutramine {u} (Compound) treats {v} (Disease) obesity
Sibutramine {u} (Compound) binds {v} (Gene) CYP3A4
Sibutramine {u} (Compound) upregulates {v} (Gene) CDK6
Sibutramine {u} (Compound) is included by {v} (Pharmacologic Class) Norepinephrine Uptake Inhibitors
Sibutramine {u} (Compound) downregulates {v} (Gene) MRPL19
Sibutramine {u} (Compound) causes {v} (Side Effect) Bursitis
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Grepafloxacin
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idelalisib
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tinzaparin
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Halazepam
Sibutramine (Compound) treats obesity (Disease)
Sibutramine (Compound) binds CYP3A4 (Gene)
Sibutramine (Compound) upregulates CDK6 (Gene)
Sibutramine (Compound) is included by Norepinephrine Uptake Inhibitors (Pharmacologic Class)
Sibutramine (Compound) downregulates MRPL19 (Gene)
Sibutramine (Compound) causes Bursitis (Side Effect)
Sibutramine may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin
Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Halazepam